ClinicalTrials.Veeva

Menu
F

Finlay Medical Research | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Olezarsen
ISIS 678354
Donanemab
Obicetrapib
sodium
Lecanemab
AVP-786
LY3002813
Inclisiran
ABBV-916

Parent organization

This site is a part of Finlay Medical Research

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 15 total trials

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (P...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: RTA 901
Drug: RTA 901-Matching Placebo

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo
Locations recently updated

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Enrolling
Alzheimer's Disease (AD)
Drug: Placebo
Drug: ABBV-916

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo
Drug: Lecanemab

The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and f...

Enrolling
Alzheimer Disease
Drug: ACU193
Drug: Placebo

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Ionis Pharmaceuticals logo
Lilly logo
Sanofi logo
AbbVie logo
A
Eisai logo
Janssen (J&J Innovative Medicine) logo
N
Novartis logo
Otsuka logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems